Agilisium, a life science-focused technology services firm has set itself a target of $0.5 billion in revenues by the next five to seven years.
The ambitious topline target comes at a time when the company, which has a large presence in Chennai, has been growing at a rate of 45 per cent YoY and is poised to reach its earlier goal of a $100 million revenue by 2027.
Speaking at a media roundtable here on Monday, Raj Babu, Founder and CEO, Agilisium said that the firm is banking heavily on the innovations and rapid growth within the Indian life science and pharma industry.
“Some of the innovation projects and transformation that Indian life science players are doing are at par if not better than what our US clients are doing,” he said.
Babu suggested that the company plans to expand India’s share in the overall revenue mix to 20 per cent by 2030. Currently, over 95 per cent of its business comes from the US market with the rest being predominantly from India and some other global markets.
Though Chennai is the company’s largest hub with a team of 700-800, Agilisium expects its long-term growth to be anchored from Hyderabad which Babu believes is going to be the life sciences hub in the Eastern Hemisphere – akin to Boston in the west.
“I think over the next few years we will grow our strength to somewhere between 2-5 thousand in Hyderabad. Most of our growth will come from there because that’s the ecosystem, and market not only in India, but all of Asia,” he said.
Interestingly, only around 30 per cent of the new talent Agilisium is hiring are from a computer science background with the company instead prioritising domain expertise.
“It is much easier to hire domain people who understand STEM, and train them in technology as opposed to hiring a computer science person and asking them to understand cell biology,” he said.
He added that the firm has recently bought in doctors, dentists, pharmacologists, biologists and PhDs to build this domain depth.
Agilisium plans to train and develop a significant Forward Deployed Expert (FDE) talent pool having already invested around ₹50 crore to reskill and deploy Agilisium’s global workforce as embedded AI transformation partners.
“We are looking at around 100 full time FDEs to be part of our teams by the end of this year and are expecting to scale this further in the coming years,” he said.
Though Life Sciences accounts for the overwhelming majority of Agilisium’s business, Babu suggested that the company is also looking to develop a considerable presence in the fast growing medtech space.
Published on October 12, 2026
